Matches in SemOpenAlex for { <https://semopenalex.org/work/W160553926> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W160553926 endingPage "9" @default.
- W160553926 startingPage "238" @default.
- W160553926 abstract "Raltegravir is a highly potent antiretroviral agent, with arguably one of the most favorable adverse event profiles in the HIV armamentarium. However, its standard twice-daily (BID) dosing schedule makes it less convenient than once-daily (QD) options. Although pharmacokinetic data suggest that QD raltegravir may provide adequate drug levels, the randomized phase III QDMRK trial (Eron, et al. Lancet Infect Dis. 2011;11:907-15) showed that 800 mg QD raltegravir failed to meet the criteria for non-inferiority when compared with 400 mg BID RAL in antiretroviral-naive HIV-infected individuals. 83% of patients in the QD arm achieved undetectable HIV viremia, in comparison with 89% in the BID arm. This was largely due to poorer efficacy among people with high baseline viral load (74 vs. 84%, respectively)." @default.
- W160553926 created "2016-06-24" @default.
- W160553926 creator A5024056045 @default.
- W160553926 date "2013-12-11" @default.
- W160553926 modified "2023-10-17" @default.
- W160553926 title "Once-daily raltegravir moving ahead." @default.
- W160553926 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24322385" @default.
- W160553926 hasPublicationYear "2013" @default.
- W160553926 type Work @default.
- W160553926 sameAs 160553926 @default.
- W160553926 citedByCount "0" @default.
- W160553926 crossrefType "posted-content" @default.
- W160553926 hasAuthorship W160553926A5024056045 @default.
- W160553926 hasConcept C112705442 @default.
- W160553926 hasConcept C126322002 @default.
- W160553926 hasConcept C142462285 @default.
- W160553926 hasConcept C159047783 @default.
- W160553926 hasConcept C197934379 @default.
- W160553926 hasConcept C2776185481 @default.
- W160553926 hasConcept C2777288759 @default.
- W160553926 hasConcept C2780404665 @default.
- W160553926 hasConcept C2993143319 @default.
- W160553926 hasConcept C3013748606 @default.
- W160553926 hasConcept C71924100 @default.
- W160553926 hasConcept C98274493 @default.
- W160553926 hasConceptScore W160553926C112705442 @default.
- W160553926 hasConceptScore W160553926C126322002 @default.
- W160553926 hasConceptScore W160553926C142462285 @default.
- W160553926 hasConceptScore W160553926C159047783 @default.
- W160553926 hasConceptScore W160553926C197934379 @default.
- W160553926 hasConceptScore W160553926C2776185481 @default.
- W160553926 hasConceptScore W160553926C2777288759 @default.
- W160553926 hasConceptScore W160553926C2780404665 @default.
- W160553926 hasConceptScore W160553926C2993143319 @default.
- W160553926 hasConceptScore W160553926C3013748606 @default.
- W160553926 hasConceptScore W160553926C71924100 @default.
- W160553926 hasConceptScore W160553926C98274493 @default.
- W160553926 hasIssue "4" @default.
- W160553926 hasLocation W1605539261 @default.
- W160553926 hasOpenAccess W160553926 @default.
- W160553926 hasPrimaryLocation W1605539261 @default.
- W160553926 hasRelatedWork W2004325424 @default.
- W160553926 hasRelatedWork W2015171620 @default.
- W160553926 hasRelatedWork W2041867451 @default.
- W160553926 hasRelatedWork W2047139068 @default.
- W160553926 hasRelatedWork W2118636292 @default.
- W160553926 hasRelatedWork W2222649585 @default.
- W160553926 hasRelatedWork W2412453981 @default.
- W160553926 hasRelatedWork W2561775660 @default.
- W160553926 hasRelatedWork W2606334551 @default.
- W160553926 hasRelatedWork W2793520024 @default.
- W160553926 hasVolume "15" @default.
- W160553926 isParatext "false" @default.
- W160553926 isRetracted "false" @default.
- W160553926 magId "160553926" @default.
- W160553926 workType "article" @default.